Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q4 2024 Earnings Conference Call February 5, 2025 8:30 AM ET
Company Participants
Guido Oelkers – Chief Executive Officer
Henrik Stenqvist – Chief Financial Officer
Lydia Abad-Franch – Head of R&D and Chief Medical Officer
Conference Call Participants
Mattias Haggblom – Handelsbanken
Brian Balchin – Jefferies
Harry Gillis – Joh. Berenberg, Gossler & Co. KG
Christopher Uhde – Seb
Erik Hultgard – Carnegie
Gonzalo Artiach Castanon – Danske Bank a/s
Shirley Chen – Barclays Bank
Viktor Sundberg – Nordea Markets
Alistair Campbell – RBC Capital Markets
Yifeng Liu – HSBC
Operator
Ladies and gentlemen, welcome to the Sobi Q4 2024 Report Conference Call and Live Webcast. I’m Sandra, the Chorus Call operator. I would like to remind you that all participants will be in a listen-only mode. And the conference is being recorded. The presentation will be followed by a Q&A session. (Operator Instructions) The conference must not be recorded for publication or broadcast.
At this time, it’s my pleasure to hand over to Guido Oelkers, CEO. Please go ahead, sir.
Guido Oelkers
Yes. Thank you. Hello, everyone. This is Guido Oelkers, CEO of Sobi. We are delighted to welcome you to the fourth quarter and the full-year 2024 conference call for investors and analysts. We posted, as mentioned, this presentation to sobi.com earlier today.
Let’s move to Slide 2. Forward-looking statement as per usual, unless otherwise stated, we will be making comments that mostly relate to the third quarter at constant – to the fourth quarter at constant exchange rate in million Swedish krona.
Today, we plan to cover the key aspects of the Q4 report. I’m joined by Henrik Stenqvist, our CFO; Lydia Abad-Franch, our Head of R&D and Chief Medical Officer. We plan to review the presentation first and then have Q&A until around 3:30 Swedish time
GIPHY App Key not set. Please check settings